Table 2.
Countries with availability of diabetes therapies, access survey by income group [16]
| Always available to purchase | Available to purchase at least three-quarters of the time | |||||
|---|---|---|---|---|---|---|
| High-income countries | Middle-income countries | Low-income countries | High-income countries | Middle-income countries | Low-income countries | |
| Metformin | 28/32 (88) | 23/36 (64) | 2/10 (20) | 31/32 (97) | 32/36 (89) | 5/10 (50) |
| Sulfonylurea | 27/32 (84) | 16/30 (53) | 1/9 (11) | 31/32 (97) | 23/30 (77) | 4/9 (44) |
| DPP4i | 24/28 (86) | 7/26 (27) | 2/8 (25) | 26/28 (93) | 16/26 (62) | 4/8 (50) |
| GLP-1RA | 20/26 (77) | 4/23 (17) | 2/6 (33) | 23/26 (88) | 11/23 (48) | 3/6 (50) |
| SGLT2i | 19/23 (83) | 3/19 (16) | 1/5 (20) | 21/23 (91) | 9/19 (47) | 2/5 (40) |
Data presented are no. (%) countries reporting 100% or > 75% availability
DPP4i dipeptidyl peptidase 4 inhibitors, GLP-1RA glucagon-like peptide 1 receptor agonists, SGLT2i sodium–glucose cotransporter 2 inhibitors